[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![whispertickers Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1937935302200373248.png) WhisperTick [@whispertickers](/creator/twitter/whispertickers) on x XX followers
Created: 2025-07-14 14:44:42 UTC

Novo Nordisk’s $NVO pipeline is challenging perceptions! Despite the buzz around Eli Lilly's $LLY lead in the weight-loss drug market, a deeper look reveals a potential edge for Novo with its oral GLP-1 therapies.

Key Points:
• Novo’s oral semaglutide shows a XX% weight reduction in trials, compared to X% for Lilly’s counterpart.
• CagriSema and Ubt251 are poised to disrupt Lilly's injectable stronghold.
• Valuation alert: Novo trades at a P/E of 15, a discount to Lilly’s XX. Is the market overlooking Novo's potential?

The landscape is changing, and Novo's advantages might surprise you. Curious? See the details here:

![](https://pbs.twimg.com/media/Gv02CWLWgAA0A7_.png)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944770031490879878/c:line.svg)

**Related Topics**
[$lly](/topic/$lly)
[eli](/topic/eli)
[novo](/topic/novo)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)
[eli lilly](/topic/eli-lilly)

[Post Link](https://x.com/whispertickers/status/1944770031490879878)